Despite growing evidence for SBRT, the jury is still out

In a recent retrospective study of patients with inoperable, nonmetastatic HCC, 1- and 2-year freedom from local progression (FFLP) rates were greater with SBRT versus radiofrequency ablation (RFA). The results of the study were reported in the Journal of Clinical Oncology by Daniel Wahl, MD, PhD, and colleagues with the University of Michigan Medical Center. Prior to this publication, data comparing SBRT and RFA were lacking.
Targeted Oncology